| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $5.9M | — | +83.7% |
| SG&A Expense | $4.4M | — | -44.3% |
| Operating Income | -$10.3M | — | +7.4% |
| Net Income | -$10.2M | — | +6.2% |
| EPS (Basic) | -$0.32 | — | +30.4% |
| EPS (Diluted) | -$0.32 | — | +30.4% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $17.7M | +84.4% | — |
| Current Assets | $18.2M | +80.0% | — |
| Total Assets | $39.0M | +28.9% | — |
| Current Liabilities | $8.1M | -14.4% | — |
| Total Liabilities | $9.3M | -4.7% | — |
| Stockholders' Equity | $29.6M | +45.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$7.9M | — | -121.7% |
| Capital Expenditures | $39K | — | +290.0% |
| Investing Cash Flow | -$39K | — | -290.0% |
| Financing Cash Flow | $16.0M | — | +1288.9% |
| Free Cash Flow | -$7.9M | — | -122.2% |